BridgeBio Oncology Therapeutics, Inc.
BBOT
$8.99
$0.111.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 128.05% | 696.00% | 94.79% | 9.78% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 98.40% | 150.11% | 26.07% | 49.76% | |
| Operating Income | -98.40% | -150.11% | -26.07% | -49.76% | |
| Income Before Tax | -97.07% | -158.37% | -30.30% | -42.82% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -97.07% | -158.37% | -30.30% | -42.82% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -97.07% | -158.37% | -30.30% | -42.82% | |
| EBIT | -98.40% | -150.11% | -26.07% | -49.76% | |
| EBITDA | -98.49% | -150.40% | -26.05% | -49.92% | |
| EPS Basic | 99.95% | 99.93% | 71.22% | 56.20% | |
| Normalized Basic EPS | 99.95% | 99.93% | 71.22% | 56.20% | |
| EPS Diluted | 99.95% | 99.93% | 71.22% | 56.20% | |
| Normalized Diluted EPS | 99.95% | 99.93% | 71.22% | 56.20% | |
| Average Basic Shares Outstanding | 436,989.62% | 391,711.71% | 352.77% | 226.14% | |
| Average Diluted Shares Outstanding | 436,989.62% | 391,711.71% | 352.77% | 226.14% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |